Pre-Print Servers

Pre-Print Servers


Gates Open Research
[Accessed 29 Jan 2022]

[No new digest content identified]


medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints – complete but unpublished manuscripts – that describe human health research conducted, analyzed, and interpreted according to scientific principles…

Comparative effectiveness of COVID-19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign
Theodore Lytras, Flora Kontopidou, Angeliki Lambrou, Sotirios Tsiodras
medRxiv 2022.01.28.22270009; doi:

Critical success factors for high routine immunization performance: A case study of Nepal
Kyra A Hester, Zoe Sakas, Anna S Ellis, Anindya Sekhar Bose, Roopa Darwar, Jhalak Gautam, Chandni Jaishwal, Hanleigh James, Pinar Keskinocak, Dima Nazzal, Emily Ogutu, Katie Rodriguez, Francisco Castillo Zunino, Sameer Dixit, Robert A. Bednarczyk, Matthew C Freeman, Vaccine Exemplars Research Consortium
medRxiv 2022.01.28.22270023; doi:

Early introduction and rise of the Omicron SARS-CoV-2 variant in highly vaccinated university populations
Brittany A Petros, Jacquelyn Turcinovic, Nicole Welch, Laura White, Eric Kolaczyk, Matthew Bauer, Michael Cleary, Sabrina Dobbins, Lynn Doucette-Stamm, Mitch Gore, Parvathy Nair, Tien Nguyen, Scott Rose, Bradford Taylor, Daniel Tsang, Erik Wendlandt, Michele Hope, Judy Platt, Karen Jacobson, Tara Bouton, Seyho Yune, Jared Auclair, Lena Landaverde, Catherine M. Klapperich, Davidson H Hamer, William P Hanage, Bronwyn MacInnis, Pardis Sabeti, John H Connor, Michael Springer
medRxiv 2022.01.27.22269787; doi:

Estimates of the impact on COVID-19 deaths of unequal global allocations of vaccines
John Paul Callan
medRxiv 2022.01.26.22269347; doi:

Is mandatory vaccination in population over 60 adequate to control the COVID-19 pandemic in E.U.?
Nikolaos Rachaniotis, Thomas Dasaklis, Filippos Fotopoulos, Michael Chouzouris, Thomas Georgiadis, Antigoni Lyberaki, Platon Tinios
medRxiv 2022.01.25.22269867; doi:

Critical success factors for high routine immunization performance: A case study of Senegal
Zoe Sakas, Kyra A. Hester, Katie Rodriguez, Saly Amos Diatta, Anna S. Ellis, Daouda Malick Gueye, Dawn Matapano, Pr Souleymane Mboup, Emily Awino Ogutu, Chenmua Yang, Robert A. Bednarczyk, Matthew C Freeman, Moussa Sarr, Vaccine Exemplars Research Consortium
medRxiv 2022.01.25.22269847; doi:

Omicron infection of vaccinated individuals enhances neutralizing immunity against the Delta variant
Khadija Khan, Farina Karim, Sandile Cele, James Emmanuel San, Gila Lustig, Houriiyah Tegally, Yuval Rosenberg, Mallory Bernstein, Yashica Ganga, Zesuliwe Jule, Kajal Reedoy, Nokuthula Ngcobo, Yoliswa Miya, Matilda Mazibuko, Ntombifuthi Mthabela, Zoey Mhlane, Nikiwe Mbatha, Jennifer Giandhari, Yajna Ramphal, Taryn Naidoo, Nithendra Manickchund, Nombulelo Magula, Salim Abdool Karim, Glenda Gray, Willem Hanekom, Anne von Gottberg, Ron Milo, Bernadett Gosnell, Richard Lessells, Tulio de Oliveira, Penny Moore, Yunus S Moosa, Alex Sigal
medRxiv 2021.12.27.21268439; doi:

COVID-19 vaccine attitude and its predictors among people living with chronic health conditions in Ibadan, Nigeria
Lucia Yetunde Ojewale, Rotimi Felix Afolabi, Adesola Ogunniyi
medRxiv 2022.01.27.22269947; doi:

The impacts of increased global vaccine sharing on the COVID-19 pandemic; a retrospective modelling study
Sam Moore, Edward M Hill, Louise J Dyson, Michael J Tildesley, Matt J Keeling
medRxiv 2022.01.26.22269877; doi:

Systematic review of social determinants of childhood immunisation in low- and middle-income countries and equity impact analysis of childhood vaccination coverage in Nigeria
Sarah V Williams, Tanimola Akande, Kaja Abbas
medRxiv 2022.01.24.22269771; doi:

South African Population Immunity and Severe Covid-19 with Omicron Variant
Shabir Madhi, Gaurav Kwatra, Jonathan E Myers, Waasila Jassat, Nisha Dhar, Christian K Mukendi, Amit Nana, Lucille Blumberg, Richard Welch, Nicoletta Ngorima-Mabhena, Portia C Mutevedzi
medRxiv 2021.12.20.21268096; doi:

Trust in the scientific research community predicts intent to comply with COVID-19 prevention measures: An analysis of a large-scale international survey dataset
Hyemin Han
medRxiv 2021.12.08.21267486; doi:

Wellcome Open Research [to 29 Jan 2022]
[Accessed 29 Jan 2022]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.
Research Article metrics
A patient satisfaction survey and educational package to improve the care of people hospitalised with COVID-19: a quality improvement project, Liverpool, UK [version 2; peer review: 2 approved]
Muhammad Shamsher Ahmad, Scott Rory Hicks, Rebecca Watson, Rajia Akter Ahmed, Lewis Jones, Marcella Vaselli, Meng-San Wu, Fatima Hayat, Libuse Ratcliffe, Mark McKenna, Paul Hine, Sylviane Defres, Tom Wingfield
Peer Reviewers Katherine Ajdukiewicz; Vishesh Paul
Wellcome Trust

Systematic Review metrics AWAITING PEER REVIEW
The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions. [version 1; peer review: awaiting peer review]
Alistair R.D. McLean, Sumayyah Rashan, Lien Tran, Lorenzo Arena, AbdulAzeez Lawal, Brittany J. Maguire, Sandra Adele, Emilia Sitsofe Antonio, Matthew Brack, Fiona Caldwell, Verena Ilona Carrara, Reema Charles, Barbara Wanjiru Citarella, Terrence B. Epie, Vitalis Fambombi Feteh, Kalynn Kennon, Gerald Jamberi Makuka, Roland Ngu, Amen-Patrick Nwosu, Sopuruchukwu Obiesie, Chinwe Ogbonnaa-Njoku, Parvesh Paul, Caitlin Richmond, Sauman Singh-Phulgenda, Samantha Strudwick, Carina S.B. Tyrrell, Kasia Stepniewska, Nathalie Strub-Wourgaft, Nicholas J. White, Philippe J. Guérin
Peer Reviewers Invited
Bundesministerium für Bildung und Forschung, Germany
International Solidarity Service, Republic and Canton of Geneva
PUBLISHED 25 Jan 2022
Background: Many available medicines have been evaluated as potential repurposed treatments for coronavirus disease 2019 (COVID-19). We summarise the registered study landscape for 32 priority pharmacological treatments identified following consultation with external experts of the COVID-19 Clinical Research Coalition.
Methods: All eligible trial registry records identified by systematic searches of the World Health Organisation International Clinical Trials Registry Platform as of 26th May 2021 were reviewed and extracted. A descriptive summary of study characteristics was performed.
Results: We identified 1,314 registered studies that included at least one of the 32 priority pharmacological interventions. The majority (1,043, 79%) were randomised controlled trials (RCTs). The sample size of the RCTs identified was typically small (median (25th, 75th percentile) sample size = 140 patients (70, 383)), i.e. individually powered only to show very large effects. The most extensively evaluated medicine was hydroxychloroquine (418 registered studies). Other widely studied interventions were convalescent plasma (n=208), ritonavir (n=189) usually combined with lopinavir (n=181), and azithromycin (n=147). Very few RCTs planned to recruit participants in low-income countries (n=14; 1.3%). A minority of studies (348, 26%) indicated a willingness to share individual participant data. The living systematic review data are available at
Conclusions: There are many registered studies planning to evaluate available medicines as potential repurposed treatments of COVID-19. Most of these planned studies are small, and therefore substantially underpowered for most relevant endpoints. Very few are large enough to have any chance of providing enough convincing evidence to change policies and practices. The sharing of individual participant data (IPD) from these studies would allow pooled IPD meta-analyses which could generate definitive conclusions, but most registered studies did not indicate that they were willing to share their data.